Neuronetics, Inc. (STIM) Operating Margin
- Operating margin · 12 months: Value -14.74%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -14.74% | Operating income / revenue. Period ending 2026-06-30. $-22.86M ÷ $155.10M × 100 ≈ -14.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -22.86M USD | Operating Income (Loss) |
| Revenue | 155.10M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 78.91M USD | Cost of Goods and Services Sold |
| Research and development | 5.87M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-22.86M | $155.10M | $78.91M | $5.87M | (m) | -14.74% |
| 2026-03-31 | $-29.42M | $151.64M | $78.91M | $6.33M | (m) | -19.40% |
| 2025-12-31 | $-31.44M | $149.16M | $76.85M | $6.58M | (m) | -21.08% |
| 2025-09-30 | $-37.87M | $129.87M | $64.38M | $10.69M | (m) | -29.16% |
| 2025-06-30 | $-38.27M | $111.11M | $48.72M | $11.60M | (m) | -34.44% |
| 2025-03-31 | $-38.72M | $89.45M | $32.64M | $12.04M | (m) | -43.29% |
| 2024-12-31 | $-34.56M | $74.89M | $20.73M | $12.77M | (m) | -46.15% |
| 2024-09-30 | $-27.52M | $72.71M | $17.67M | $9.21M | (m) | -37.85% |
| 2024-06-30 | $-28.66M | $72.06M | $19.26M | $8.95M | (m) | -39.77% |
| 2024-03-31 | $-27.51M | $73.22M | $19.83M | $9.07M | (m) | -37.56% |
| 2023-12-31 | $-30.55M | $71.35M | $19.64M | $9.52M | (m) | -42.82% |
| 2023-09-30 | $-33.85M | $69.23M | $19.49M | $10.45M | (m) | -48.90% |
| 2023-06-30 | $-32.44M | $67.85M | $16.94M | $10.64M | (m) | -47.81% |
| 2023-03-31 | $-34.88M | $66.56M | $16.14M | $10.32M | (m) | -52.40% |
| 2022-12-31 | $-35.11M | $65.21M | $15.48M | $9.34M | (m) | -53.85% |
| 2022-09-30 | $-34.29M | $62.03M | $14.63M | $7.94M | (m) | -55.28% |
| 2022-06-30 | $-34.02M | $59.33M | $14.21M | $7.17M | (m) | -57.34% |
| 2022-03-31 | $-30.79M | $57.20M | $12.92M | $7.42M | (m) | -53.82% |
| 2021-12-31 | $-27.56M | $55.31M | $11.65M | $7.92M | (m) | -49.83% |
| 2021-09-30 | $-23.32M | $55.87M | $11.88M | $8.29M | (m) | -41.73% |
| 2021-06-30 | $-18.56M | $54.52M | $11.39M | $8.67M | (m) | -34.04% |
| 2021-03-31 | $-18.85M | $50.06M | $10.96M | $8.49M | (m) | -37.66% |
| 2020-12-31 | $-22.31M | $49.24M | $11.55M | $9.20M | (m) | -45.30% |
| 2020-09-30 | $-26.59M | $51.02M | $12.01M | $11.34M | (m) | -52.11% |
| 2020-06-30 | $-30.49M | $54.57M | $13.54M | $12.87M | (m) | -55.88% |
| 2020-03-31 | $-30.24M | $61.40M | $15.39M | $13.98M | (m) | -49.25% |
| 2019-12-31 | $-26.93M | $62.66M | $15.39M | $13.75M | (m) | -42.98% |
| 2019-09-30 | $-25.65M | $60.94M | (m) | $11.72M | (m) | -42.10% |
| 2019-06-30 | $-23.66M | $58.67M | (m) | $10.36M | (m) | -40.32% |
| 2019-03-31 | $-22.29M | $55.35M | (m) | $9.46M | (m) | -40.26% |
| 2018-12-31 | $-19.83M | $52.78M | (m) | $8.23M | (m) | -37.58% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-14.22M | $43.06M | (m) | $7.46M | (m) | -33.04% |
| 2017-12-31 | $-13.61M | $40.43M | (m) | $7.94M | (m) | -33.66% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-9.34M | $34.23M | (m) | $8.22M | (m) | -27.28% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |